Award
NIH Reporter #1UG3AG101657-01
Repurposing a Reverse Transcriptase Inhibitor To Target Retrotransposons and Prevent Alzheimer's Disease in People with Down Syndrome: A Two-Phase UG3/UH3 Clinical Drug Development Program
Recipient
Brigham and Women's Hospital
Award Amount
$1,478,201.00
Ceiling
$1,478,201.00
Awarded
August 06, 2026
Identifier
1UG3AG101657-01
NIH/NIA funds a clinical drug development program to repurpose a reverse transcriptase inhibitor to prevent Alzheimer's disease in people with Down syndrome, including phase 1b and 2a trials.
Description
The project aims to evaluate the safety, pharmacology, and efficacy of lamivudine in preventing Alzheimer's in people with Down syndrome. The project includes a phase 1b safety trial and a phase 2a proof-of-concept trial. Funded by the NIH/NIA under grant number 1UG3AG101657-01, involving multiple investigators and interdisciplinary collaboration.